Coya Therapeutics (COYA) Income from Continuing Operations (2022 - 2026)
Coya Therapeutics (COYA) posted Income from Continuing Operations of 7206990.0 for Q1 2026, up 15.88% sequentially from 8567956.0 in Q4 2025, and up 1.37% YoY from 7109910.75 in Q1 2025.
Coya Therapeutics (COYA) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Coya Therapeutics has reported Income from Continuing Operations for 5 years, with the latest figure at 7206990.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 1.37% year-over-year to 7206990.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26731706.0 (up 13.13% YoY) and the FY2025 annual result came in at 21303368.0, down 42.98% from the prior year.
- Income from Continuing Operations climbed to 7206990.0 in Q1 2026 per COYA's latest filing, from 8567956.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1700361.0 in Q1 2022 and troughed at 12209369.0 in Q4 2024.
- A 5-year average of 5301644.53 and a median of 4530578.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 220.46% in 2024, then surged 41.88% in 2025.
- Over 5 years, Income from Continuing Operations stood at 3003518.0 in 2022, then dropped by 26.85% to 3809961.0 in 2023, then sank by 220.46% to 12209369.0 in 2024, then gained by 29.82% to 8567956.0 in 2025, then increased by 15.88% to 7206990.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 7206990.0, 8567956.0, and 4861783.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | -6.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.64 Mn |
| Mar 31, 2026 | -7.21 Mn |
| Dec 31, 2025 | -8.57 Mn |
| Sep 30, 2025 | -4.86 Mn |
| Jun 30, 2025 | -6.09 Mn |
| Mar 31, 2025 | -7.31 Mn |
| Dec 31, 2024 | -12.21 Mn |
| Sep 30, 2024 | -8.36 Mn |
| Jun 30, 2024 | -2.89 Mn |
| Mar 31, 2024 | -5.05 Mn |
| Dec 31, 2023 | -3.81 Mn |
| Sep 30, 2023 | -4.53 Mn |
| Jun 30, 2023 | -4.44 Mn |
| Mar 31, 2023 | -3.98 Mn |
| Dec 31, 2022 | -3.00 Mn |
| Sep 30, 2022 | -2.66 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Mar 31, 2022 | -1.70 Mn |